Head and neck squamous cell carcinomas (HNSCC) are a group of cancers that affect cells in and around our mouth and nose.

Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor ...

With 890,000 new cases and 450,000 deaths annually, HNSCC accounts for roughly 4.5% of cancer diagnoses and deaths worldwide.

Head and Neck Squamous Cell Carcinoma (HNSCC), also commonly known as Head and Neck cancers are a group of cancers that originate in the head and neck region of the human body. These include the oral ...

Researchers developed a diagnostic test based on the LIMA1-alpha protein to distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone, without the need for ...

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Given its rising global incidence, poor prognosis, high recurrence, and metastatic potential, there is an ...

Geoffrey Y. Ku, MD: I definitely agree it's a little bit of a niche topic here in the US, because numerically, we probably see 4000-5000 patients with esophageal squamous cell cancer every year.

Key Takeaways Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy ...

Key Takeaways Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 ...

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally advanced squamous cell carcinoma of the head and neck. "This is the ...